Why Monkey Farms Don't Breed More Despite 3x Price Surge: The Dual-Role Trap
Experimental cynomolgus monkeys now cost up to $36,000 each, triple the price from 18 months ago, yet farms refuse to expand breeding because each monkey serves as both a sellable product and a future breeding machine, creating a 6-7 year feedback loop where high prices incentivize selling breeding stock, worsening future shortages.
Demand: Monkeys Are Single-Use in Preclinical Trials
Drug developers need non-human primates for preclinical safety and pharmacokinetics studies before human trials. Over 90% of experimental monkeys in China are cynomolgus monkeys. A typical PK study requires 18 monkeys; a toxicokinetics study requires 40 — 58 monkeys total per program. Critically, each monkey can be used only once in a formal experiment . Demand therefore tracks innovative drug R&D activity. From 2020–2022, hot financing pushed monkey prices from under 50,000 RMB to over 200,000 RMB; the 2023 funding cooldown crashed prices below 100,000 RMB. Recently, demand rebounded: 2,997 domestic clinical trial approvals in 2025 (+18% YoY), and H1 2026 out-licensing deal value hit $99.7B (~2x full-year 2024). Industry estimates annual demand at ~30,000 monkeys with a ~10,000 shortfall.
Supply: Each Monkey Is Both Product and "Breeding Machine"
A juvenile female monkey faces two mutually exclusive paths:
Sell at 2–3 years old for immediate revenue (the "product" path).
Retain as breeding stock, mature at ~4 years, then produce one offspring per year (the "machine" path).
This dual identity creates a long production lag: from retaining a weaned female to having her offspring ready for sale takes 6–7 years . The 2020 price spike's retained breeders only now start yielding saleable offspring — but demand has already cycled up, down, and up again.
The Reinforcing Loop: Higher Prices → Fewer Breeders → Even Higher Prices
When prices exceed 100,000 RMB, farms rarely retain weaned females; most adopt "sell whatever you have." Yicai Global reports this has even led to selling off breeding females. Data from 26 mid-to-large farms show breeding females fell from ~69,000 (end-2020) to ~66,000 (2023), while the share of females aged 8+ rose from 56.8% to ~80% — the herd is shrinking and aging.
The causal loop diagram (system dynamics) captures this:
Price ↑ → Farms sell more, retain fewer breeders → ~4 years later: fewer breeding females → ~2–3 years later: fewer saleable juveniles → Price ↑ further
This reinforcing loop (R) has a 6–7 year delay: today's decisions manifest only years later, when they can no longer be reversed.
Simulation: Three Strategies Compared
A simple annual model (female matures at 4, offspring sellable at 3, demand jumps 25% in year 1 then flat, price = demand / saleable monkeys) tests three rules:
Sell-more-when-price-rises (current behavior)
Retain-more-when-price-rises (textbook expectation)
Constant retention ratio (reference)
Early years: Sell-more strategy looks better — price rises only to 1.38× baseline by year 3, while retain-more hits 1.78× because it withholds juveniles.
Long term: Sell-more's breeding herd shrinks 31% by year 15, pushing price to 2.1× and still climbing — "the more it rises, the tighter supply gets." Retain-more survives the early spike; new breeders come online by year 14, price returns to baseline, but then overshoots into a glut — the classic hog cycle.
Only a steady, long-term retention plan (gray dashed line) yields stability, but that requires sacrificing current profits for a 6–7 year horizon.
Who Pays for the Loop?
Pharma companies and research institutes: Must book monkeys 5–6 months ahead; a full preclinical package costs ~20M RMB, with monkey cost now a major component.
Monkey-holding firms: Since 2018, large CROs (e.g., Joinnova/Zhaoyan) acquired farms. In Q3 2026, Joinnova reported 930M RMB net profit, of which 866M came from biological asset fair-value gains — price appreciation alone creates paper profit without adding a single monkey.
Why Not Import?
Cynomolgus monkeys are CITES Appendix II. Since 2023, China approved imports from Cambodia, Laos, Vietnam, and Syria, but compliant overseas suppliers are limited and domestic quarantine facilities are backlogged. A 2019 import window brought ~10,000 monkeys, but subsequently tuberculosis detection rates rose sharply in domestic farms. Qualified monkeys must test negative for at least five pathogens. Imports can only partially fill the gap.
Where the Model May Be Wrong
Demand isn't static: If innovative drug funding cools again, the sell-more shortage eases; if it stays hot, the retain-more glut arrives earlier and harder.
Farms don't react only to spot price: They watch orders, peers, policy. Leading CROs are accelerating farm build-out; coordinated long-term retention could flatten the "rise-further" curve.
Alternatives are advancing: In vitro models, organoids, and regulatory moves to reduce animal use may shift demand within years.
The exact numbers (e.g., 2.1× at year 15) are illustrative. The structural insight stands: when an asset is both the product and the means of producing that product, and production takes many years, price signals push toward short-term gain while the supply penalty arrives years later.
Two Diagnostic Questions for Any "Price Up, Supply Stuck" Story
Is it its own "mother machine"? Does selling a unit simultaneously reduce future capacity? Pigs, cattle, fruit trees, seeds, skilled craftsmen all share this duality.
How long from decision to output? The longer the lag, the more violent the cycles — don't expect relief in a few months.
If the answer to both is "yes, and a long time," today's high prices are likely seeding even higher prices years down the road.
References:
[1] Yicai Global: Reporting on experimental monkey prices, breeding cycles, supply-demand gap, and import access (incl. NIFDC & SIBS tender prices), 2026.
[2] Lanjing News: Coverage of monkey quotes, breeding female counts & age structure, import access, Nov 2026.
[3] The Paper: "Experimental monkeys hit 260,000 RMB, price doubled in under a year; farms: no pre-orders, come back early next year," Nov 9, 2026.
[4] Tonghuashun Finance: Joinnova 2026 Q3 report coverage, Oct 29, 2026.
[5] Causal loop diagram and annual simulation are author-created; parameters are illustrative.
Signed-in readers can open the original source through BestHub's protected redirect.
This article has been distilled and summarized from source material, then republished for learning and reference. If you believe it infringes your rights, please contactand we will review it promptly.
How this landed with the community
Was this worth your time?
0 Comments
Thoughtful readers leave field notes, pushback, and hard-won operational detail here.
